J. LoPiccolo

发表

Assembly and Molecular Architecture of the Phosphoinositide 3-Kinase p85α Homodimer*

Seung Joong Kim, B. Chait, A. Sali, 2015, The Journal of Biological Chemistry.

Assembly of the p 85 α homodimer 1 Assembly and Molecular Architecture of the Phosphoinositide 3-Kinase p 85 α homodimer

Seung Joong Kim, B. Chait, A. Sali, 2015 .

Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells

J. LoPiccolo, J. Gills, P. Dennis, 2012, Cell Death and Disease.

Targeting Akt in cancer therapy.

J. LoPiccolo, J. Gills, P. Dennis, 2007, Anti-cancer drugs.

Different inhibition of Gβγ-stimulated class IB phosphoinositide 3-kinase (PI3K) variants by a monoclonal antibody. Specific function of p101 as a Gβγ-dependent regulator of PI3Kγ enzymatic activity.

Prajwal, Roger L. Williams, J. LoPiccolo, 2015, The Biochemical journal.

Ceramide mediates nanovesicle shedding and cell death in response to phosphatidylinositol ether lipid analogs and perifosine

J. LoPiccolo, J. Gills, P. Dennis, 2012, Cell Death and Disease.

Identification of the Rab5 binding site in p110β: assays for PI3Kβ binding to Rab5.

A. Bresnick, J. LoPiccolo, H. Dbouk, 2015, Methods in molecular biology.

Rac1-stimulated macropinocytosis enhances Gβγ activation of PI3Kβ.

Zahra Erami, A. Bresnick, J. LoPiccolo, 2017, The Biochemical journal.

E. Lipson, J. LoPiccolo, M. Brener, 2019, Hepatology.

In reply to: Is Nodular Regenerative Hyperplasia an Immune‐Mediated Phenomenon?

E. Lipson, J. LoPiccolo, M. Brener, 2019 .

Nodular Regenerative Hyperplasia Associated With Immune Checkpoint Blockade

E. Lipson, J. LoPiccolo, M. Brener, 2018, Hepatology.

Utilizing Electronic Health Records (EHR) and Tumor Panel Sequencing to Demystify Prognosis of Cancer of Unknown Primary (CUP) patients

Dong Liu, J. LoPiccolo, K. Kehl, 2022, medRxiv.

Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy

J. LoPiccolo, J. Gills, P. Dennis, 2008, Autophagy.

Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.

J. LoPiccolo, P. Dennis, G. Blumenthal, 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Combining Nelfinavir With Chloroquine Inhibits In Vivo Growth of Human Lung Cancer Xenograft Tumors

J. LoPiccolo, J. Gills, P. Dennis, 2021, In Vivo.

PTEN hamartomatous tumor syndromes (PHTS): rare syndromes with great relevance to common cancers and targeted drug development.

J. LoPiccolo, P. Dennis, M. Ballas, 2007, Critical reviews in oncology/hematology.

Nelfinavir, A Lead HIV Protease Inhibitor, Is a Broad-Spectrum, Anticancer Agent that Induces Endoplasmic Reticulum Stress, Autophagy, and Apoptosis In vitro and In vivo

Robert H. Shoemaker, William D. Figg, Erin R. Gardner, 2007, Clinical Cancer Research.

Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma.

S. Steinberg, J. LoPiccolo, P. Dennis, 2007, Lung cancer.

Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series

E. Lipson, J. LoPiccolo, W. Sharfman, 2019, Journal of Immunotherapy for Cancer.

A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors

S. Steinberg, C. Helsabeck, J. LoPiccolo, 2014, Oncotarget.

A Central Role for Foxp3+ Regulatory T Cells in K-Ras-Driven Lung Tumorigenesis

S. Steinberg, J. LoPiccolo, R. Memmott, 2009, PloS one.

Corticosteroid Use and Pneumocystis Pneumonia Prophylaxis: A Teachable Moment.

E. Lipson, J. LoPiccolo, S. Mehta, 2018, JAMA internal medicine.

Nelfinavir , ALeadHIVProtease Inhibitor , Is aBroad-Spectrum , AnticancerAgent that InducesEndoplasmicReticulum Stress , Autophagy , andApoptosis Invitro and Invivo

R. Shoemaker, P. Steeg, Carolyn J. M. Best, 2007 .

Exceptional Response to Bromodomain and Extraterminal Domain Inhibitor Therapy With BMS-986158 in BRD4-NUTM1 NUT Carcinoma Harboring a BRD4 Splice Site Mutation.

P. Jänne, L. Chirieac, J. LoPiccolo, 2023, JCO precision oncology.

Landscape of pathogenic germline variants in patients with lung cancer.

R. Nussbaum, J. LoPiccolo, E. Esplin, 2022, Journal of Clinical Oncology.

A phase I study of nelfinavir, an FDA approved HIV protease inhibitor, in adults with refractory solid tumors.

C. Helsabeck, J. LoPiccolo, P. Dennis, 2009, Journal of Clinical Oncology.

Machine learning for genetics-based classification and treatment response prediction in cancer of unknown primary

J. LoPiccolo, K. Kehl, M. Hassett, 2023, Nature Medicine.